Publications by authors named "Mayte Coiras"

Retinoic acid inducible gene I (RIG-I)-like receptors (RLRs), including RIG-I, MDA5 and LGP2, recognize viral RNA to mount an antiviral interferon (IFN) response RLRs share three different protein domains: C-terminal domain, DExD/H box RNA helicase domain, and an N-terminal domain with two tandem repeats (CARDs). LGP2 lacks tandem CARD and is not able to induce an IFN response. However, LGP2 positively enhances MDA5 and negatively regulates RIG-I signaling.

View Article and Find Full Text PDF
Article Synopsis
  • - HIV-1 infection persists due to long-term viral reservoirs in latently infected CD4 T cells, prompting the need for strategies to stimulate cytotoxic immunity, including the "Shock and Kill" approach.
  • - Ponatinib, a tyrosine kinase inhibitor used for chronic myeloid leukemia, has shown effectiveness against HIV-1 and may enhance the immune response against both cancer and viral infections.
  • - In a study of patients with chronic myeloid leukemia who switched from imatinib to ponatinib, results indicated that ponatinib treatment significantly reduced HIV-1 infection rates and increased the cytotoxic response from peripheral blood mononuclear cells, with effects lasting at least 12 months post-treatment.
View Article and Find Full Text PDF
Article Synopsis
  • Post-coronavirus disease condition (PCC) continues to impact many people, but there's a lack of reliable diagnostic biomarkers to differentiate it from recovery after acute COVID-19.
  • A study compared biomarkers between two groups: people with PCC and those who recovered from COVID-19 within three months, both consisting of 85 individuals.
  • The results showed PCC individuals had significant changes in 49 out of 167 markers, and a specific panel of four biomarkers could distinguish PCC from recovery with over 88% accuracy.
View Article and Find Full Text PDF
Article Synopsis
  • After mild COVID-19, some individuals develop a condition called Post-COVID condition (PCC) characterized by lingering symptoms and persistent immune system changes.
  • A study compared the immune responses of people with PCC to those with mild, severe, and critical COVID-19, focusing on specific CD4+ T helper cell types.
  • Results indicated that people with PCC had a unique immune profile, including low Th1 cells, high Th2 response, and elevated pro-inflammatory Th9 and Th17 cells, which may hinder the body's ability to fight off infections and contribute to prolonged symptoms.
View Article and Find Full Text PDF
Article Synopsis
  • * Dasatinib, a medication used for chronic myeloid leukemia, shows promise against HIV-1 by preserving the antiviral activity of the SAMHD1 protein in CD4+ T cells and reducing the phosphorylation that inactivates it, inhibiting HIV-1 infection in macrophages.
  • * Short-term dasatinib treatment lowers inflammatory cytokines in macrophages while maintaining some antiviral responses, suggesting that combining dasatinib with ART could effectively target HIV-1 reservoirs and reduce inflammation in people living with HIV.
View Article and Find Full Text PDF

Introduction: HIV-1 infection may produce a detrimental effect on the immune response. Early start of antiretroviral therapy (ART) is recommended to preserve the integrity of the immune system. In fact, people with HIV (PWH) and normal CD4/CD8 ratio appear not to be more susceptible to severe forms of COVID-19 than the general population and they usually present a good seroconversion rate in response to vaccination against SARS-CoV-2.

View Article and Find Full Text PDF
Article Synopsis
  • * A study focused on 29 CML patients, some on TKIs and others in treatment-free remission, comparing their immune responses after full COVID-19 vaccination with 20 healthy individuals over 17 months.
  • * Results showed that while CML patients developed a strong immune response similar to healthy individuals, their antibody-dependent cytotoxic activity was reduced, leading to slightly higher rates of mild COVID-19 breakthrough infections, particularly in those avoiding treatment.
View Article and Find Full Text PDF
Article Synopsis
  • - The study focuses on the effectiveness of COVID-19 vaccination in individuals with oncohematological diseases (OHD) who received hematopoietic stem cell transplants (HSCT), addressing significant morbidity and mortality rates prior to vaccination.
  • - It was found that these individuals maintained low but protective levels of neutralizing antibodies against SARS-CoV-2 after undergoing HSCT, indicating some persistent immune protection despite B-cell deficiencies.
  • - Results showed that although cellular immunity was impaired in those who had allogeneic HSCT, infections that occurred post-transplant were mild, reinforcing the necessity and safety of COVID-19 vaccination for this vulnerable group.
View Article and Find Full Text PDF

The main objective of this study was to determine the influence of the cytotoxic activity of peripheral blood mononuclear cells (PBMCs) on the outcome of unvaccinated individuals with critical COVID-19 admitted to the ICU. Blood samples from 23 individuals were collected upon admission and then every 2 weeks for 13 weeks until death (Exitus group) ( = 13) or discharge (Survival group) ( = 10). We did not find significant differences between groups in sociodemographic, clinical, or biochemical data that may influence the fatal outcome.

View Article and Find Full Text PDF

Up to half of individuals who contract SARS-CoV-2 develop symptoms of long-COVID approximately three months after initial infection. These symptoms are highly variable, and the mechanisms inducing them are yet to be understood. We compared plasma cytokine levels from individuals with long-COVID to healthy individuals and found that those with long-COVID had 100% reductions in circulating levels of Interferon Gamma (IFNγ) and Interleukin-8 (IL-8).

View Article and Find Full Text PDF

Macrophages are one of the main cellular targets of human immunodeficiency virus type 1 (HIV-1). Macrophage infection by HIV-1 is inefficient due to the presence of the viral restriction factor sterile alpha motif and histidine aspartic acid domain containing protein 1 (SAMHD1). human monocyte-derived macrophages (MDMs) express SAMHD1 in an equilibrium between active (unphosphorylated) and inactive (phosphorylated) states.

View Article and Find Full Text PDF

The humoral immune response developed after receiving the full vaccination schedule against COVID-19 is impaired in individuals who received anti-CD20 therapy 6-9 months before vaccination. However, there is little information about the cellular immune responses elicited in these individuals. In this study, we analyzed the humoral and cellular immune responses in 18 individuals with hematological disease who received the last dose of rituximab 13.

View Article and Find Full Text PDF

Up to half of individuals who contract SARS-CoV-2 develop symptoms of long-COVID approximately three months after initial infection. These symptoms are highly variable, and the mechanisms inducing them are yet to be understood. We compared plasma cytokine levels from individuals with long-COVID to healthy individuals and found that those with long-COVID had 100% reductions in circulating levels of interferon gamma (IFNγ) and interleukin-8 (IL-8).

View Article and Find Full Text PDF

The clinical presentations of COVID-19 may range from an asymptomatic or mild infection to a critical or fatal disease. Several host factors such as elderly age, male gender, and previous comorbidities seem to be involved in the most severe outcomes, but also an impaired immune response that causes a hyperinflammatory state but is unable to clear the infection. In order to get further understanding about this impaired immune response, we aimed to determine the association of specific HLA alleles with different clinical presentations of COVID-19.

View Article and Find Full Text PDF

There is now sufficient evidence to support that vitamin D deficiency may predispose to SARS-CoV-2 infection and increase COVID-19 severity and mortality. It has been suggested that vitamin D supplementation may be used prophylactically as an affordable and safe strategy that could be added to the existing COVID-19 standard treatment. This multicenter, single-blinded, prospective randomized pilot clinical trial aimed to evaluate the safety, tolerability, and effectiveness of 10,000 IU/day in comparison with 2000 IU/day of cholecalciferol supplementation for 14 days to reduce the duration and severity of COVID-19 in 85 hospitalized individuals.

View Article and Find Full Text PDF

Background: Although human immunodeficiency virus type 1 (HIV-1) reservoir size is very stable under antiretroviral therapy (ART), individuals exposed to the Hepatitis C virus (HCV) (chronically coinfected and spontaneous clarifiers) show an increase in HIV reservoir size and in spliced viral RNA, which could indicate that the viral protein regulator Tat is being more actively synthesized and, thus, could lead to a higher yield of new HIV. However, it is still unknown whether the effect of HCV elimination with direct-acting antivirals (DAAs) could modify the HIV reservoir and splicing. Methods: This longitudinal study (48 weeks’ follow-up after sustained virological response) involves 22 HIV+-monoinfected individuals, 17 HIV+/HCV- spontaneous clarifiers, and 24 HIV+/HCV+ chronically infected subjects who eliminated HCV with DAAs (all of them aviremic, viral load < 50).

View Article and Find Full Text PDF

LGMDD2 is a rare form of muscular dystrophy characterized by one of the three heterozygous deletions described within the gene that result in the addition of a 15-amino acid tail in the C-terminus.TNPO3 is involved in the nuclear import of splicing factors and acts as a host cofactor for HIV-1 infection by mechanisms not yet deciphered. Further characterization of the crosstalk between HIV-1 infection and LGMDD2 disease may contribute to a better understanding of both the cellular alterations occurring in LGMDD2 patients and the role of TNPO3 in the HIV-1 cycle.

View Article and Find Full Text PDF

Individuals with oncohematological diseases (OHD) may develop an impaired immune response against vaccines due to the characteristics of the disease or to its treatment. Humoral response against SARS-CoV-2 has been described to be suboptimal in these patients, but the quality and efficiency of the cellular immune response has not been yet completely characterized. In this study, we analyzed the early humoral and cellular immune responses in individuals with different OHD after receiving one dose of an authorized vaccine against SARS-CoV-2.

View Article and Find Full Text PDF

Main cause of severe illness and death in COVID-19 patients appears to be an excessive but ineffectual inflammatory immune response that may cause severe acute respiratory distress syndrome (ARDS). Vitamin D may favour an anti-inflammatory environment and improve cytotoxic response against some infectious diseases. A multicenter, single-blind, prospective, randomized clinical trial was approved in patients with COVID-19 pneumonia and levels of 25-hydroxyvitamin D (25(OH)D) of 14.

View Article and Find Full Text PDF

Oncohematological patients show a low immune response against SARS-CoV-2, both to natural infection and after vaccination. Most studies are focused on the analysis of the humoral response; therefore, the information available about the cellular immune response is limited. In this study, we analyzed the humoral and cellular immune responses in nine individuals who received chemotherapy for their oncohematological diseases, as well as consolidation with autologous stem cell transplantation (ASCT), after being naturally infected with SARS-CoV-2.

View Article and Find Full Text PDF
Article Synopsis
  • Long-COVID is a new syndrome marked by symptoms lingering for over four weeks after a COVID-19 infection, with potential causes still being researched.
  • A study on Spanish individuals found that those with Long-COVID had significantly higher levels of certain immune cells, indicating a strong antiviral response.
  • By analyzing clinical symptoms and demographic factors, researchers developed a Random Forest algorithm that accurately predicted Long-COVID status, suggesting that identifying specific biomarkers could enhance patient management.
View Article and Find Full Text PDF

HIV-1 infection of myeloid cells is associated with the induction of an IFN response. How HIV-1 manipulates and subverts the IFN response is of key interest for the design of therapeutics to improve immune function and mitigate immune dysregulation in people living with HIV. HIV-1 accessory genes function to improve viral fitness by altering host pathways in ways that enable transmission to occur without interference from the immune response.

View Article and Find Full Text PDF

SARS-CoV-2 infection causes COVID-19, ranging from mild to critical disease in symptomatic subjects. It is essential to better understand the immunologic responses occurring in patients with the most severe outcomes. In this study, parameters related to the humoral immune response elicited against SARS-CoV-2 were analysed in 61 patients with different presentations of COVID-19 who were recruited in Hospitals and Primary Healthcare Centres in Madrid, Spain, during the first pandemic peak between April and June 2020.

View Article and Find Full Text PDF
Article Synopsis
  • HIV-1 forms a latent reservoir in CD4+ T cells, making it hard to completely eliminate the virus with antiretroviral therapy (ART).
  • A study found that combining dasatinib treatment for chronic myeloid leukemia (CML) with ART in HIV-infected patients significantly reduced the size and reactivation of this viral reservoir.
  • Results showed that patients on both treatments had a more than 5-fold decrease in latently infected cells and over 4-fold reduction in reactivated proviruses, suggesting that dasatinib could enhance HIV treatment outcomes.
View Article and Find Full Text PDF